Since FMRP regulates glycolysis and OXPHOS, combining its inhibition with glycolytic blockers such as 2-deoxyglucose (2-DG) or HK2 inhibitors could impair tumor energy metabolism and sensitize tumors to therapy. Here, FMR1 is linked to neoplasm.